Evidence map›Paper›PMID 37742913›Full record

ArticleThe Journal of investigative dermatology2024

Sclerotic-Type Cutaneous Chronic Graft-Versus-Host Disease Exhibits Activation of T Helper 1 and OX40 Cytokines.

Madeline Kim, Yael Renert-Yuval, Polina Stepensky, Ehud Even-Or, Irina Zaidman, Tahel Fachler, Michal Neumark, Mariana Zamir, Monali NandyMazumdar, Digpal Gour and 11 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of investigative dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 3 countries.

Madeline KimDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Yael Renert-YuvalDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Pediatric Dermatology Unit, Schneider Children's Medical Center of Israel, Petah Tikva, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Polina StepenskyDepartment of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Ehud Even-OrDepartment of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Irina ZaidmanDepartment of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Tahel FachlerDepartment of Dermatology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Michal NeumarkDepartment of Dermatology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Mariana ZamirDepartment of Dermatology, Sheba Medical Center, Tel Hashomer, Israel.
Monali NandyMazumdarDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Digpal GourDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Paola FacherisDepartment of Dermatology, IRCCS Humanitas Research Hospital, Milano, Italy.
Britta CarrollDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Ying LiuDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Mitchelle L Yu EkeyDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Elizabeth AndrewsDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Marguerite MearimanDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Michael AngelovDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Swaroop BoseDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Yeriel D EstradaDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Vered Molho-PessachDepartment of Dermatology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. Electronic address: rverem@hadassah.org.il.
Emma Guttman-YasskyDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: emma.guttman@mountsinai.org.
Icahn School of Medicine at Mount Sinai · USHebrew University of Jerusalem · ILIRCCS Humanitas Research Hospital · ITSheba Medical Center · ILTel Aviv University · IL

Funding

Skin Biology and Diseases Resource-based Center at Mount SinaiP30AR079200 · NIAMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Elena Ezhkova · 2021 to 2026
$5.2M
NIAMS NIH HHS P30 AR079200
6 · The paper itself

Abstract

Sclerotic-type cutaneous chronic graft-versus-host disease is a severe complication of allogeneic hematopoietic stem cell transplantation, with profound morbidity. A dearth of effective, targeted treatment options necessitates further investigation into the molecular mechanisms underlying this T-cell-mediated disease. In this study, we compared the transcriptome in skin biopsies from pediatric and young adult (aged <25 years) patients with sclerotic-type cutaneous chronic graft-versus-host disease (n = 7) with that in demographically matched healthy controls (n = 8) and patients with atopic dermatitis (n = 10) using RNA sequencing with RT-PCR and immunohistochemistry validation. Differential expression was defined as fold change > 1.5 and false discovery rate < 0.05. Sclerotic-type cutaneous chronic graft-versus-host disease exhibited strong and significant T helper (Th)1 skewing through key related cytokines and chemokines (CXCL9/10/11, IFNG/IFN-γ, STAT1/signal transducer and activator of transcription 1). Several markers related to the TSLP-OX40 axis were significantly upregulated relative to those in both controls and lesional atopic dermatitis, including TNFSF4/OX40L, TSLP, and IL33, as well as fibroinflammatory signatures characterized in a prior study in systemic sclerosis. Gene set variation analysis reflected marker-level findings, showing the greatest enrichment of the Th1 and fibroinflammatory pathways, with no global activation identified in Th2 or Th17/Th22. Cell-type deconvolution revealed a significant representation of macrophages and vascular endothelial cells. Sclerotic-type cutaneous chronic graft-versus-host disease in young patients may therefore be characterized by strong Th1-related upregulation with a unique TSLP-OX40 signature, suggesting new therapeutic avenues for this devastating disease.

Indexed as

Bronchiolitis Obliterans SyndromeDermatitis, AtopicGraft vs Host DiseaseSkin DiseasesChildCytokinesEndothelial CellsHumansOX40 LigandTh2 CellsYoung AdultCytokinesOX40 LigandTNFSF4 protein, human

Identifiers

PMID37742913
PMCPMC11447555
OpenAlexW4386947125

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.